Replay available

Johnson & Johnson (JNJ) Q2 2026 Earnings Call

Johnson & Johnson (NYSE: JNJ) Q2 2026 earnings conference call, held 2026-07-15. Replay captured from the company's public earnings webcast.

Wed, July 15, 2026 at 8:30 AMendedReplay
Johnson & Johnson (JNJ) Q2 2026 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Ryan Kors

Vice President of Investor Relations

Joaquin Duato

Chairman and Chief Executive Officer

Joe Wolk

Executive Vice President and Chief Financial Officer

Jennifer Taubert

Executive Vice President, Worldwide Chairman of Innovative Medicine

John Reed

Executive Vice President, Innovative Medicine Research and Development

Tim Schmidt

Executive Vice President, Worldwide Chairman of MedTech

Chris Schott

Analyst, J.P. Morgan

Asad Haider

Analyst, Goldman Sachs

Larry Bielsen

Analyst, Wells Fargo

Terrence Flynn

Analyst, Morgan Stanley

Joanne Wunsch

Analyst, Citibank

Vamo Devan

Analyst, Guggenheim Securities

Alex Hammond

Analyst, Wolf Research

Jason Bedford

Analyst, Raymond James

Mike Notokovic

Analyst, TD Cal

Replay transcript excerpt

Good morning and welcome to Johnson & Johnson's second quarter 2026 earnings conference call. All participants will be in a listen-only mode until the question and answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. If you experience technical difficulties during the conference, you may press star zero to reach the operator. I will now turn the conference call over to Johnson & Johnson. You may begin. Hello everyone, this is Ryan Kors, Vice President of Investor Relations for Johnson & Johnson. I'm excited to be here today and to lead the Investor Relations team moving forward. Welcome to our company's review of business results for the second quarter of 2026 and our financial outlook for the full year. First, a few logistics. As a reminder, today's presentation and associated schedules are available on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position, and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on the current expectations of future events using the information available as of the date of this recording. They are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. The description of these risks, uncertainties, and other factors can be found in our SEC filings, including our 2025 Form 10-K, which is available at investor.jnj.com and on the SEC's website. Additionally, several of the products and compounds discussed today are being developed in collab...

More from Johnson & Johnson